News | June 10, 2019

Deciphera Pharmaceuticals, Inc. Expands Pipeline with Potential First-in-Class Autophagy Inhibitor to Treat Mutant RAS Cancers -DCC-3116 Selectively Targets ULK Kinase, an Initiating Protein that Activates Autophagy – -Company to Host a Webcast on Tuesday, June...

News | June 10, 2019

Aptinyx Reports Positive Top-line Data from Phase 2 Study of NYX-2925 in Patients with Fibromyalgia, Demonstrating Significant Effects on Both Biomarkers and Patient-Reported Pain NYX-2925 demonstrated statistically significant effects on a range of neuroimaging...

News | April 4, 2019

TigerConnect Named a Top Technology Company in Santa Monica 04.25.19 In the News Home / Newsroom /TigerConnect Named a Top Technology Company in Santa Monica Originally posted in The Tech Tribune Best Technology Company in Santa MonicaThe Tech Tribune staff has...

News | May 29, 2019

ARVINAS RECEIVES FAST TRACK DESIGNATION FOR ITS TARGETED PROTEIN DEGRADER ARV-110 AS A TREATMENT FOR MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER ARV-110 is Arvinas’ first clinical-stage drug in the innovative field of targeted protein degradation,...

News | April 30, 2019

Aptinyx Reports Positive Data from Phase 1 Study of Novel NMDA Receptor Modulator, NYX-458, in Healthy Volunteers Favorable overall safety, tolerability, and pharmacokinetic profile—no serious adverse events reported across wide dose range Achieved ample CNS exposure...